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Introduction: Hypercoagulable states have been reported as a predisposing factorfor ischemic stroke, especially 
among young patients. This may haveimplications on therapeutic management and secondary prevention. We have studied the frequency of prothrombotic abnormalities 
in young patients with ischaemic stroke, as other classic risk factors are less common in this group. Materials and methods: All patients under 50 with ischemic stroke 
admitted to the Service of Neurology from January 2010 through June 2011were studied. We analysed risk factors, including the presence of hypercoagulable states, and 
outcome. These patients were prospectively studied. The ESO 2008 diagnostic criteria for ischemic stroke are used. Titration of natyral anticoagulants was done 7 ± 2 
days after cerebral infarction. Besides the routine tests, the following activity tests were performed: protein C, Protein S, homocysteinemia and antithrombin titration. 
Results: We included 36 patients,under 50 years of age, diagnosed with cerebral infarction of undetermined cause randomly presented to the University Service of 
Neurology January 2010 – June 2011. There were 16 males (44.4%) with a mean age of 30 years old (23 - 48). The mean age for 20 females (55.6%) was 28 years old 
(22 - 45). 1 patient (2.7%),hadantithrombin deficiency. Isolated protein S deficiency was detected in 5 cases (13.8%); in 1 case we observed the association between 
protein S deficiency and antiphospholipid antibodies; protein C deficiency was seen in 2 case ( 5.5%). Conclusions: The hypercoagulable states are common in young 
patients with ischaemic stroke, so we recommend the screening for hypercoagulable states in all young patients with ischemic stroke.   
 
Introduction  
 
Thrombosis is in the core of the pathological physiology of ischemic stroke. The thrombosis is 
secondarily activated, following a vascular pathology in most cases, but ischemic stroke may be the consequence 
of primarily disorders of hemostatic mechanisms, in a part of them, as well. Consequently the undiserable 
thrombus formation can happen in the cerebral circulation. In this context, there has been defined an interactive 
system, functioning between the cell and fluid components of hemostasis, and in this system is found to be in 
balance the inhibitory and excitatory coagulation factors.  
The main factors of this system, are: 
1. The platelets; 
2. The coagulation factors and their inhibitors; 
3. The fibrinolytic system; 
4. The vascular endothelium. 
 
The Coagulation Factors and their Inhibitors 
 
There are a few factors and co-factors interacting between each other in the coagulation system, 
throughout which the thrombin effect consists on transformation of fibrinogen in insoluble fibrin from a soluble 
protein precursor. There is evident an important role of thrombin in hemostasis system, because it is one of the
Hypercoagulability and Ischemic Stroke in 
Young Patients 
 
Healthcare 
Keywords:  ischemic stroke, hyporcoagulable 
state, prothrombotic abnormalities. 
Abstract 
 Volume 5, issue 2, 2016  e-ISSN: 1857-8187   p-ISSN: 1857-8179                                                                                                            
 Page | 61  
Anglisticum Journal (IJLLIS), Volume: 5 | Issue: 2, February 2016|  
 
most important platelets agonists, and it plays an excitatory effect in an anticoagulant natyral system (protein C – 
protein S –thrombomoduline system). The final path of forming thrombin by prothrombin, include the formation 
of an excitatory complex with Ca for the Xth and Vth factor of coagulation. It happens in a phospholipid surface 
of activatet platelets. The final common pathway, bounds together the intrinsic coagulation system activated 
from the surface contact and the extrinsic system, activated from the tissue factor release (thromboplastyn). As 
the result of coagulation and platelet activation, a hemostatic cap is formed, consisting of aggregated platelets 
and fibrin.  
 
The Coagulation Inibitors  
 
The physiological inhibitory mechanisms, oppose the uncontrolled fibrin formation. They are set three 
most important coagulation inhibitors: the antithrombin (known before as antithrombin III); the protein C; and 
the protein S (the protein C cofactor). The antithrombin III is a seric proteases inhibitor, whose action is focused 
against XIIa, XIaandIXain the extrinsic coagulation path. Its inhibition effect is empowered from the 
glucosaminoglycans (heparin – like molecules), as well as from heparin given for therapeutic goal. The activated 
protein C, inhibits the activated coagulation factors VIIIa and Va. The protein S is very important for the protein 
C activity, functioning as a protein C cofactor. On the other hand, the thrombin and thrombomodylin are very 
important in the protein C activation, as endothelderivant cofactor.  
 
The Fibrinolysis  
 
The fibrinolyticmechanism provides a further control on thrombus formation process. The plasmin 
formed under the effect of plasminogen activated factor (t-PA), can dissolve the fibrin into a solublefibrinolytic 
degradation product. The fibrinolytic process is modulated by the interaction between the excitatory and 
inhibitory coagulation factors in the coagulation system.  
 
Hemostatic Mechanisms  
 
Disorders and the Trombosis It is identified a sure and clear link between the coagulation mechanisms 
and occlusive arterial disease, including even the stroke. The hemostatic mechanisms are as included in the 
evolution and progression of the atheromas, as important for platelet / fibrinotyc thrombus during the acute 
phase of occlusive event. Prothrombotyc condition is defined as a special situation, with multifactorial causes / 
mechaisms.In specific way, some of these conditions determine as hemostatic disorders are clearly related with a 
high thrombotic risk. Below are listed some of these conditions: 
1. Congenital trombophylia – it is caused by the deficiency of a natyral anticoagulation factor (Protein 
C, protein S, orantithrombin); 
2. Acquired disorder = the primary antiphospholypidsyndrom (it is in relation with the presence of 
autoantibody towards phospholipid, and this is accompanied by high thrombotic risk); 
3. Myeloproliferativediseases: essential thrombocytemi and & polycytemiaverae (thrombocytosis 
with/out high platelet reactivity, is in the base of high thrombotic tendency). 
 
Congenital Trombophylia  
 
There are identified the most important and frequent disorders of hemostatic control mechanisms, that 
predispose for thrombosis, as below: 1. The antithrombin III deficiency; 2. Protein C deficiency; 3. Protein S 
deficiency. It was discovered on 1965 the correlation between the thromboembolism and hereditary deficiency 
of antithrombin III (O. Egeberg 1965: Inherited antithrombin III deficiency causing thrombophilia). The 
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antithrombin III deficiency, with the prevalence 1/20 000 – 1/40 000, is found to be responsible for 2 – 5 % of 
venous thromboembolism. These thrombotic events are rare in children, but the thrombotic risk for persons 15 – 
30 years, is estimated to be almost 65% (J. Hirsh & Co 1989: Congenital antithrombin III deficiency). The 
protein C and protein S are vitamin K dependent protein. The hereditary deficiency of protein C and S are 
described for the first time on 1981(JH Griffin & Co 1981: Deficiency of protein C in congenital thrombotic 
disease), and 1984 (PC Comp & Co 1984: Familial protein S deficiency associated with recurrent thrombosis). 
The prevalence of protein C deficiency is undefined, but in healthy blood donors it is found 1/200 persons 
(JMiletich 1987: Absence of thrombosis and subjects with heterozygous protein C deficiency). The symptomatic 
deficiency is rarer, and it is found to be 1/36 000 individë (CL Gladson 1988: The frequency of type I 
heterozygous protein C deficiency in 141 unrelated young patients with venous thrombosis). Based on the above 
figures, we can say that heterozygote condition may be clinically silent. The homozygote conditions are more 
often associated with life threatening thrombosis (ATripodi 1990: Asymptomatic homozygous protein C 
deficiency). The plasmatic protein S is free in circulation. It”sfree state, may play the cofactor role for the 
activated protein C. The most frequent protein S deficiency is a heterozygous condition, in which there are very 
low levels of free protein S , and almost all this amount of protein S is bounded by its binding protein C4bBP 
(C4b binding protein). There are so rare the conditions in which as levels of fraction of free protein S, as level of 
bounded protein Sare reduced. The protein S deficiency has almost the same thrombotic risk as protein C 
deficiency (L Engesser1987: Hereditary protein S deficiency, clinical manifestations). 
 
Results  
 
We included 36 patients, under 50 years of age, diagnosed with cerebral infarction of undetermined 
cause randomly presented to the University Service of Neurology fromJanuary 2010until June 2011.These 
patients were prospectively studied. The ESO 2008 diagnostic criteria for ischemic stroke are used. We analysed 
risk factors, including the presence of hypercoagulable states, and outcome. Titration of natyral anticoagulants 
was done 7 ± 2 days after cerebral infarction. Besides the routine tests, the following activity tests were 
performed: protein C, Protein S, homocysteinemia and antithrombin titration. We didn’t use patients 
stratification based on ischemic lesion localization. 36 patients were divided patients based on their age, using as 
a borderline 50 years. There were 16 males (44.4%) with a mean age of 30 years old (23 - 48) and 20 females 
(55.6%) with a mean age 28 years old (22 - 45). Excluding all other risk factor for ischemic stroke, we dosed 
antithrombin III, protein C and protein S for all these patients. 
 
Antithrombin IIII deficiency 
They were identified 1 patient (2.7%), with antitrombin III deficiency. They are a few studies referring 
antithrombin deficiency as correlated with ischemic stroke. One study refers 3 patients with antithrombin 
deficiency of 45 studied, but its mentioned to be temporary reduction (JErnerudh 1990: Antithrombin III 
deficiency in ischaemic stroke). In another study performed in Turkey and published on 2007 were 
retrospectively assessed risk factors in children with arterial stroke, were found 2 from 31 patients studied with 
antitrombin III deficiency (S Gokben 2007: Arterial ischemic stroke in childhood: risk factors and outcome in 
old versus new era). All the studies, despite the frequency of antithrombin III deficiency, included patients 45 
until 55 years. (Angela Mirela Soare 2010: efficiencies of protein C, S and antithrombin and factor V Leiden and 
thë risk of ischemic strokes).   
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Protein C deficiency 
In our study there were 2 patients (5.5%) with protein C deficiency. They are reported different data for 
protein C deficiency in different study, but we should emphasize that these patients (protein C deficiency) have 
stroke in younger age than other patients without that deficiency (J Hirsh 2004: Overview of thrombosis and its 
treatment). In another study, only one from 329 patients (15 – 45 years) have protein C deficiency. Therefore, its 
not a strong relation between protein C deficiency and arterial stroke (MMoster 2003: Coagulopathies and 
arterial stroke). 
 
Protein S deficiency 
In our study, there were 5 patients (13.8%), with protein S deficiency. In different study we found 
relatively high number of patients with protein S deficiency, as: 13.8% (5/36 patients), 19% (8/35 patients, 23% 
(19/98 patients) according to the patients age. (M. Moster2003: Coagulopathies and arterial stroke). It was 
supposed that these factors level decreas in acute phase of thrombtic event. Protein S level decreases notably 
after acute activation of complement, consequentlyit is recommended titration of Protein S after 6 months. 
(Martin PJ & Co 1997: Causes of ischaemic stroke in the young). Conclusions The hypercoagulable states are 
common in young patients with ischaemic stroke, so we recommend the screening for hypercoagulable states in 
all young patients with ischemic stroke.  
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